Refractory Celiac Disease

Georgia Malamut; Joseph A. Murray; Christophe Cellier

doi:10.1016/j.giec.2012.07.007

Refractory Celiac Disease

Georgia Malamut, Joseph A. Murray, Christophe Cellier

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

A small subset of patients with celiac disease become refractory to a gluten-free diet, with persistent or recurrent symptoms of malabsorption and intestinal villous atrophy. This condition, defined as refractory celiac disease (RCD), is diagnosed after other small bowel diseases with villous atrophy are excluded. RCD is subdivided into 2 subgroups: type I RCD and type II RCD (RCDII). This latter condition is considered a low-grade intraepithelial lymphoma and has a poor prognosis. This article reviews the clinical and pathologic features of RCD and recent pathogenic findings in RCDII, offering a model to study how inflammation can drive T-cell lymphomagenesis.

Original language	English (US)
Pages (from-to)	759-772
Number of pages	14
Journal	Gastrointestinal Endoscopy Clinics of North America
Volume	22
Issue number	4
DOIs	https://doi.org/10.1016/j.giec.2012.07.007
State	Published - Oct 2012

Keywords

Aberrant intraepithelial lymphocytes
Immunosuppressive treatments
Refractory celiac disease

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1016/j.giec.2012.07.007

Cite this

@article{26c556c6f0074ac2a11178cde60248f6,

title = "Refractory Celiac Disease",

abstract = "A small subset of patients with celiac disease become refractory to a gluten-free diet, with persistent or recurrent symptoms of malabsorption and intestinal villous atrophy. This condition, defined as refractory celiac disease (RCD), is diagnosed after other small bowel diseases with villous atrophy are excluded. RCD is subdivided into 2 subgroups: type I RCD and type II RCD (RCDII). This latter condition is considered a low-grade intraepithelial lymphoma and has a poor prognosis. This article reviews the clinical and pathologic features of RCD and recent pathogenic findings in RCDII, offering a model to study how inflammation can drive T-cell lymphomagenesis.",

keywords = "Aberrant intraepithelial lymphocytes, Immunosuppressive treatments, Refractory celiac disease",

author = "Georgia Malamut and Murray, {Joseph A.} and Christophe Cellier",

year = "2012",

month = oct,

doi = "10.1016/j.giec.2012.07.007",

language = "English (US)",

volume = "22",

pages = "759--772",

journal = "Gastrointestinal Endoscopy Clinics of North America",

issn = "1052-5157",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Refractory Celiac Disease

AU - Malamut, Georgia

AU - Murray, Joseph A.

AU - Cellier, Christophe

PY - 2012/10

Y1 - 2012/10

N2 - A small subset of patients with celiac disease become refractory to a gluten-free diet, with persistent or recurrent symptoms of malabsorption and intestinal villous atrophy. This condition, defined as refractory celiac disease (RCD), is diagnosed after other small bowel diseases with villous atrophy are excluded. RCD is subdivided into 2 subgroups: type I RCD and type II RCD (RCDII). This latter condition is considered a low-grade intraepithelial lymphoma and has a poor prognosis. This article reviews the clinical and pathologic features of RCD and recent pathogenic findings in RCDII, offering a model to study how inflammation can drive T-cell lymphomagenesis.

AB - A small subset of patients with celiac disease become refractory to a gluten-free diet, with persistent or recurrent symptoms of malabsorption and intestinal villous atrophy. This condition, defined as refractory celiac disease (RCD), is diagnosed after other small bowel diseases with villous atrophy are excluded. RCD is subdivided into 2 subgroups: type I RCD and type II RCD (RCDII). This latter condition is considered a low-grade intraepithelial lymphoma and has a poor prognosis. This article reviews the clinical and pathologic features of RCD and recent pathogenic findings in RCDII, offering a model to study how inflammation can drive T-cell lymphomagenesis.

KW - Aberrant intraepithelial lymphocytes

KW - Immunosuppressive treatments

KW - Refractory celiac disease

UR - http://www.scopus.com/inward/record.url?scp=84867686509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867686509&partnerID=8YFLogxK

U2 - 10.1016/j.giec.2012.07.007

DO - 10.1016/j.giec.2012.07.007

M3 - Review article

C2 - 23083992

AN - SCOPUS:84867686509

SN - 1052-5157

VL - 22

SP - 759

EP - 772

JO - Gastrointestinal Endoscopy Clinics of North America

JF - Gastrointestinal Endoscopy Clinics of North America

IS - 4

ER -

Refractory Celiac Disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this